Summary of Significant Accounting Policies - Revenue Recognition (Details) |
3 Months Ended | 6 Months Ended | ||||||
|---|---|---|---|---|---|---|---|---|
|
Feb. 22, 2026
USD ($)
|
Apr. 12, 2024 |
Jun. 30, 2026
USD ($)
|
Jun. 30, 2025
USD ($)
|
Jun. 30, 2026
USD ($)
Promise
Agreement
|
Jun. 30, 2026
EUR (€)
Promise
Agreement
|
Jun. 30, 2025
USD ($)
|
Dec. 31, 2025
USD ($)
|
|
| Disaggregation of Product Revenue | ||||||||
| Number of distribution agreements | Agreement | 1 | 1 | ||||||
| Number of promises | Promise | 2 | 2 | ||||||
| Initial term of contract | 5 years | 5 years | ||||||
| license fees recognized | $ 43,000 | $ 43,000 | $ 86,000 | $ 86,000 | ||||
| Deferred revenue | 468,000 | 468,000 | $ 552,000 | |||||
| Non-refundable license fee | 215,040 | € 200,000 | ||||||
| Royalty expense | 142,000 | 39,000 | 284,000 | 78,000 | ||||
| Revenue | 1,225,000 | 2,979,000 | 21,497,000 | 5,193,000 | ||||
| April 2024 Agreement for Gelclair | ||||||||
| Disaggregation of Product Revenue | ||||||||
| Initial term of contract | 5 years | |||||||
| Royalty expense | 142,000 | 39,000 | 284,000 | 78,000 | ||||
| Mytesi | ||||||||
| Disaggregation of Product Revenue | ||||||||
| Product revenue | 1,200,000 | 2,800,000 | 2,100,000 | 4,900,000 | ||||
| License granted | 1,200,000 | 2,800,000 | 2,100,000 | 4,900,000 | ||||
| Mytesi | Specialty Pharmacies | ||||||||
| Disaggregation of Product Revenue | ||||||||
| Product revenue | 0 | 2,500,000 | 24,000,000,000 | 4,200,000 | ||||
| License granted | 0 | 2,500,000 | 24,000,000,000 | 4,200,000 | ||||
| Canalevia-CA1 | ||||||||
| Disaggregation of Product Revenue | ||||||||
| Product revenue | 0 | 60,000 | 270,000 | 77,000 | ||||
| License granted | 0 | 60,000 | 270,000 | 77,000 | ||||
| Neonorm | ||||||||
| Disaggregation of Product Revenue | ||||||||
| Product revenue | 7,000 | 14,000 | 14,000 | 30,000 | ||||
| License granted | 7,000 | 14,000 | 14,000 | 30,000 | ||||
| License | ||||||||
| Disaggregation of Product Revenue | ||||||||
| license fees recognized | $ 3,000,000 | 0 | 19,000,000 | |||||
| Revenue recognized | 6,000 | 27,000 | 15,000 | 52,000 | ||||
| Financial liability | 0 | 0 | ||||||
| Revenue | $ 43,000 | $ 43,000 | $ 19,086,000 | $ 86,000 | ||||
| X | ||||||||||
- Definition The initial period of contract. No definition available.
|
| X | ||||||||||
- Definition Non-refundable license fee. No definition available.
|
| X | ||||||||||
- Definition The number of distribution agreements. No definition available.
|
| X | ||||||||||
- Definition Number of promises. No definition available.
|
| X | ||||||||||
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Cash received from licensees for license fees during the current period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|